Drug Profile
Research programme: heat shock protein 90 modulators - Evotec SE/Genextra
Alternative Names: HSP90-targeted compounds - Evotec SE/GenextraLatest Information Update: 26 Sep 2019
Price :
$50
*
At a glance
- Originator Evotec AG; Genextra
- Developer Evotec SE; Genextra
- Class Small molecules
- Mechanism of Action Heat-shock protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 07 Jul 2009 Discontinued - Preclinical for Cancer in Germany (unspecified route)
- 07 Jul 2009 Discontinued - Preclinical for Cancer in Italy (unspecified route)
- 07 Jul 2009 Discontinued - Preclinical for Cancer in United Kingdom (unspecified route)